Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03284424
Registration number
NCT03284424
Ethics application status
Date submitted
14/09/2017
Date registered
15/09/2017
Date last updated
5/10/2023
Titles & IDs
Public title
Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629)
Query!
Scientific title
A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)
Query!
Secondary ID [1]
0
0
MK-3475-629
Query!
Secondary ID [2]
0
0
3475-629
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Squamous Cell Carcinoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Non melanoma skin cancer
Query!
Cancer
0
0
0
0
Query!
Kidney
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - Pembrolizumab
Experimental: R/M cSCC cohort - Participants with R/M cSCC receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to approximately 2 years.
Experimental: LA cSCC cohort - Participants with LA cSCC receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to approximately 2 years.
Other interventions: Pembrolizumab
IV infusion
Query!
Intervention code [1]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Objective Response Rate (ORR)
Query!
Assessment method [1]
0
0
ORR was defined as the percentage of participants who have best response of Complete Response (CR: Disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). ORR per RECIST 1.1 as assessed by blinded independent central review (BICR) is presented.
Query!
Timepoint [1]
0
0
Up to approximately 31.8 months (database cutoff date 29-Jul-2020)
Query!
Secondary outcome [1]
0
0
Duration of Response (DOR)
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Up to approximately 56 months
Query!
Secondary outcome [2]
0
0
Disease Control Rate (DCR)
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Up to approximately 56 months
Query!
Secondary outcome [3]
0
0
Progression-free Survival (PFS)
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Up to approximately 56 months
Query!
Secondary outcome [4]
0
0
Overall Survival (OS)
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Up to approximately 56 months
Query!
Secondary outcome [5]
0
0
Number of Participants Who Experienced One or More Adverse Events (AEs)
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Up to approximately 56 months
Query!
Secondary outcome [6]
0
0
Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
Up to approximately 56 months
Query!
Eligibility
Key inclusion criteria
- R/M cSCC cohort only:
- Has cSCC that is either metastatic defined as disseminated disease, and/or
unresectable disease that is not curable by surgery or radiation.
- Has histologically-confirmed cSCC as the primary site of malignancy (metastatic skin
involvement from another primary cancer or from an unknown primary cancer is not
permitted).
- LA cSCC cohort only:
- Must be ineligible for surgical resection.
- Participants who received prior radiation therapy (RT) to index site or must be deemed
to be not eligible for RT.
- Participants who received prior systemic therapy for curative intent are eligible
regardless of regimen.
- R/M cSCC cohort only:
- Has metastatic disease defined as disseminated disease distant to the initial/primary
site of diagnosis, and/or must have locally recurrent disease that has been previously
treated (with either surgery or radiotherapy), and is not amenable to either curative
surgery or radiotherapy.
- Has measurable disease based on RECIST 1.1 as assessed by the central imaging vendor.
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within
10 days prior to the start of study treatment.
- Has adequate organ function.
- Has a tissue sample adequate for programmed death-ligand 1 (PD-L1) testing as
determined by central laboratory testing prior to study allocation.
- Has a life expectancy >3 months.
- Female participants of childbearing potential must agree to use an adequate method of
contraception during the study treatment period and for at least 120 days after the
last dose of study treatment.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Has cSCC that can be cured with surgical resection, radiotherapy, or with a
combination of surgery and radiotherapy.
- Has any other histologic type of skin cancer other than invasive squamous cell
carcinoma as the primary disease under study, e.g. basal cell carcinoma that has not
been definitively treated with surgery or radiation, Bowen's disease, Merkel cell
carcinoma (MCC), melanoma.
- Has had any prior allogeneic solid organ or bone marrow transplantation.
- Has received prior therapy with an anti-programmed death protein-1 (anti-PD-1),
anti-programmed death-ligand 1 (anti-PD-L1), or anti-PD-L2 agent or with an agent
directed to another stimulatory or co-inhibitory T cell receptor (e.g. cytotoxic
T-lymphocyte associated protein 4 [CTLA-4], Tumor necrosis factor receptor
superfamily, member 4 [OX-40], tumor necrosis factor receptor superfamily member 9
[CD137]).
- Has received prior systemic anti-cancer therapy including investigational agents
within 4 weeks prior to study allocation.
(Notes: Participants must have recovered from all AEs due to previously administered
therapies to = Grade 1 or baseline. If a participant received major surgery, they must have
recovered adequately from the toxicity and/or complications from the intervention prior to
starting study treatment.)
- Has received prior radiotherapy within 2 weeks of start of study treatment.
- Is currently participating in or has participated in a study of an investigational
agent or has used an investigational device within 4 weeks prior to the first dose of
study treatment.
- Has known active central nervous system (CNS) metastases and/or carcinomatous
meningitis.
- Has an active autoimmune disease that has required systemic treatment in the past 2
years (e.g. with use of disease-modifying agents, anticoagulants, corticosteroids or
immunosuppressive drugs).
- Has a history of (noninfectious) pneumonitis that required steroids or has current
pneumonitis.
- Has an active infection requiring systemic therapy.
- Has a known history of human immunodeficiency virus (HIV) infection.
- Has a known history of Hepatitis B or known active Hepatitis C virus infection.
- Is pregnant or breastfeeding or expecting to conceive or father children within the
projected duration of the study, starting with the screening visit through 120 days
after the last dose of study treatment.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
26/10/2017
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
13/09/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
159
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD
Query!
Recruitment hospital [1]
0
0
Orange Health Services ( Site 0406) - Orange
Query!
Recruitment hospital [2]
0
0
Southern Medical Day Care Centre ( Site 0408) - Wollongong
Query!
Recruitment hospital [3]
0
0
Royal Brisbane and Women s Hospital ( Site 0407) - Herston
Query!
Recruitment hospital [4]
0
0
Princess Alexandra Hospital ( Site 0405) - Woolloongabba
Query!
Recruitment hospital [5]
0
0
The Townsville Hospital ( Site 0404) - Douglas
Query!
Recruitment hospital [6]
0
0
Lismore Base Hospital ( Site 0402) - Lismore
Query!
Recruitment postcode(s) [1]
0
0
2800 - Orange
Query!
Recruitment postcode(s) [2]
0
0
2500 - Wollongong
Query!
Recruitment postcode(s) [3]
0
0
4029 - Herston
Query!
Recruitment postcode(s) [4]
0
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [5]
0
0
4814 - Douglas
Query!
Recruitment postcode(s) [6]
0
0
2480 - Lismore
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Connecticut
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
District of Columbia
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Indiana
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Kansas
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Massachusetts
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Nevada
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
New Jersey
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Oklahoma
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Pennsylvania
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
South Dakota
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Texas
Query!
Country [13]
0
0
Canada
Query!
State/province [13]
0
0
New Brunswick
Query!
Country [14]
0
0
Canada
Query!
State/province [14]
0
0
Ontario
Query!
Country [15]
0
0
Canada
Query!
State/province [15]
0
0
Quebec
Query!
Country [16]
0
0
France
Query!
State/province [16]
0
0
Cedex 9
Query!
Country [17]
0
0
France
Query!
State/province [17]
0
0
Bobigny
Query!
Country [18]
0
0
France
Query!
State/province [18]
0
0
Lille
Query!
Country [19]
0
0
France
Query!
State/province [19]
0
0
Limoges
Query!
Country [20]
0
0
France
Query!
State/province [20]
0
0
Marseille
Query!
Country [21]
0
0
France
Query!
State/province [21]
0
0
Nice cedex 3
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
Paris
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Pierre Benite
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Reims
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Villejuif
Query!
Country [26]
0
0
Germany
Query!
State/province [26]
0
0
Essen
Query!
Country [27]
0
0
Germany
Query!
State/province [27]
0
0
Hannover
Query!
Country [28]
0
0
Germany
Query!
State/province [28]
0
0
Kiel
Query!
Country [29]
0
0
Germany
Query!
State/province [29]
0
0
Mannheim
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Tuebingen
Query!
Country [31]
0
0
Israel
Query!
State/province [31]
0
0
Haifa
Query!
Country [32]
0
0
Israel
Query!
State/province [32]
0
0
Petah Tikva
Query!
Country [33]
0
0
Israel
Query!
State/province [33]
0
0
Ramat Gan
Query!
Country [34]
0
0
Israel
Query!
State/province [34]
0
0
Tel-Aviv
Query!
Country [35]
0
0
Mexico
Query!
State/province [35]
0
0
Jalisco
Query!
Country [36]
0
0
Mexico
Query!
State/province [36]
0
0
Nuevo Leon
Query!
Country [37]
0
0
Mexico
Query!
State/province [37]
0
0
Chihuahua
Query!
Country [38]
0
0
Mexico
Query!
State/province [38]
0
0
Mexico City
Query!
Country [39]
0
0
Norway
Query!
State/province [39]
0
0
Bergen
Query!
Country [40]
0
0
Norway
Query!
State/province [40]
0
0
Oslo
Query!
Country [41]
0
0
Spain
Query!
State/province [41]
0
0
Barcelona
Query!
Country [42]
0
0
Spain
Query!
State/province [42]
0
0
Madrid
Query!
Country [43]
0
0
Spain
Query!
State/province [43]
0
0
Valencia
Query!
Country [44]
0
0
United Kingdom
Query!
State/province [44]
0
0
Wirral
Query!
Country [45]
0
0
United Kingdom
Query!
State/province [45]
0
0
London
Query!
Country [46]
0
0
United Kingdom
Query!
State/province [46]
0
0
Truro
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Merck Sharp & Dohme LLC
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475)
in adult participants with recurrent or metastatic(R/M) cutaneous Squamous Cell Carcinoma
(cSCC) or locally advanced (LA) unresectable cSCC that is not amenable to surgery and/or
radiation and/or systemic therapies.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03284424
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Medical Director
Query!
Address
0
0
Merck Sharp & Dohme LLC
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03284424
Download to PDF